madman
Super Moderator
* Because the pathophysiological mechanisms underlying PFS remain unknown, causal treatment is currently
not possible, and interventions are symptomatic and supportive. Current recommendations emphasize the need for an integrated biopsychosocial approach that considers biological, psychological, and social aspects.
Figure 1. Post-finasteride syndrome – symptoms
==============
Abstract
Post-finasteride syndrome is a complex condition characterized by psychological, sexual, and somatic symptoms observed in patients currently or previously treated with 5α-reductase inhibitors. Although these agents are commonly used in the management of benign prostatic hyperplasia and androgenetic alopecia, an increasing number of cases report persistent adverse effects even after treatment discontinuation. The lack of clearly defined pathophysiological mechanisms and the limited availability of clinical research complicate the diagnosis and management of post-finasteride syndrome. This paper reviews the current understanding of post-finasteride syndrome, including its potential molecular pathways, clinical presentation, and therapeutic approaches. Strong evidence supports the existence of post-finasteride syndrome, and the European Medicines Agency has recognized suicidal ideation as an adverse effect of finasteride administered at doses used to treat androgenetic alopecia. Various therapies can be administered to alleviate the symptoms of post-finasteride syndrome, and effective communication with patients is essential to ensure that adverse events are recognized and addressed. An interdisciplinary framework should be used for the implementation of treatment with 5α-reductase inhibitors, with patients undergoing thorough physical and mental health assessments prior to treatment initiation.
==============
That 5α-reductase inhibitors are lipophilic and can cross the blood–brain barrier, thereby exerting effects on the central nervous system, is not widely recognized [10]. The enzyme 5α-reductase plays a crucial role in the metabolism of neuroactive steroids within the central nervous system. Three isoforms of this enzyme have been identified in the brain, where they participate in the conversion of testosterone and progesterone to their active metabolites of dihydrotestosterone and dihydroprogesterone, respectively.
These products are further metabolized into neuroactive derivatives such as allopregnanolone, isopregnanolone, 5α-androstan-3α,17β-diol, and 5α-androstan-3β, 17β-diol. These compounds modulate the activity of neurosteroid receptors, including the GABA-A receptor complex, thereby playing an important role in regulating emotional, cognitive, and behavioral processes [11].
As an inhibitor of type II 5α-reductase and, to a lesser extent, type I, finasteride disrupts this metabolic pathway. Such disruption may lead to significant alterations in the concentrations of neuroactive steroids in both plasma and cerebrospinal fluid.
==========
Conclusions
For lower urinary tract symptoms in patients at risk of developing PFS, phosphodiesterase type 5 inhibitors, which can improve sexual function and urinary flow without directly affecting the androgen hormonal axis, may be a treatment option. Drugs from this class, along with α-adrenergic antagonists, may serve as pharmacologic alternatives for symptomatic benign prostatic hyperplasia. If pharmacotherapy is not effective in alleviating symptoms, patients can be offered a wide range of procedural interventions tailored to their individual needs and clinical condition.
Because the pathophysiological mechanisms underlying PFS remain unknown, causal treatment is currently
not possible, and interventions are symptomatic and supportive. Current recommendations emphasize the need for an integrated biopsychosocial approach that considers biological, psychological, and social aspects. Psychological and psychiatric support plays a key role and includes cognitive behavioral therapy, treatment of coexisting depressive or anxiety disorders, with a preference for antidepressants with a minimal impact on sexual function (e.g., bupropion, mirtazapine), and sex therapy incorporating sensate focus techniques and motivational interviewing.
PDE5 inhibitors or intracavernosal injections are used to treat erectile dysfunction, and supportive measures may include supplementation with, for example, vitamin D, vitamin E, L-arginine, or L-carnitine. These supplements may positively influence nitric oxide metabolism and vascular function.
Cilio et al. [22] describe PFS as a relatively rare syndrome, with symptoms that may persist for more than a year after finasteride discontinuation. The authors also discuss several potential factors that may contribute to PFS, including androgen receptor gene polymorphisms and changes in the gut microbiota. In another study, authored by Thaibah and published in 2025 [23], an extensive dataset involving more than 9,400 participants with PFS was analyzed. The results revealed that nearly 18% of participants reported suicidal ideation and 7% had attempted suicide. Based on these findings, the European Medicines Agency formally recognized suicidal ideation as an adverse effect of finasteride at a dose of 1 mg, the dose used to treat androgenetic alopecia.
Cilio et al. [22] discussed PFS and its core side effects, which require a complex diagnostic process. The authors emphasized that the absence of clearly established pathophysiological mechanisms cannot be grounds for denying the existence of the syndrome, especially given the increasing number of consistent clinical observations.
A promising, although still experimental, area of research is the development of therapies targeting neuroactive steroids and modulation of androgen receptor expression. However, none of the available therapeutic regimens guarantees complete remission of symptoms. The goal of treatment is the gradual alleviation of symptoms and improvement of patients’ quality of life. Given the possible influence of the nocebo effect, effective communication with the patient is crucial, including ensuring that reported complaints are taken seriously and fostering a trust-based therapeutic relationship. Treatment should be implemented within an interdisciplinary framework involving physicians, psychologists, and sexologists. In every case, the decision to initiate therapy with a 5α-reductase inhibitor should be preceded by a thorough assessment of the patient’s physical and mental health and by obtaining informed consent after discussion of the potential benefits and risks
not possible, and interventions are symptomatic and supportive. Current recommendations emphasize the need for an integrated biopsychosocial approach that considers biological, psychological, and social aspects.
Figure 1. Post-finasteride syndrome – symptoms
==============
Abstract
Post-finasteride syndrome is a complex condition characterized by psychological, sexual, and somatic symptoms observed in patients currently or previously treated with 5α-reductase inhibitors. Although these agents are commonly used in the management of benign prostatic hyperplasia and androgenetic alopecia, an increasing number of cases report persistent adverse effects even after treatment discontinuation. The lack of clearly defined pathophysiological mechanisms and the limited availability of clinical research complicate the diagnosis and management of post-finasteride syndrome. This paper reviews the current understanding of post-finasteride syndrome, including its potential molecular pathways, clinical presentation, and therapeutic approaches. Strong evidence supports the existence of post-finasteride syndrome, and the European Medicines Agency has recognized suicidal ideation as an adverse effect of finasteride administered at doses used to treat androgenetic alopecia. Various therapies can be administered to alleviate the symptoms of post-finasteride syndrome, and effective communication with patients is essential to ensure that adverse events are recognized and addressed. An interdisciplinary framework should be used for the implementation of treatment with 5α-reductase inhibitors, with patients undergoing thorough physical and mental health assessments prior to treatment initiation.
==============
That 5α-reductase inhibitors are lipophilic and can cross the blood–brain barrier, thereby exerting effects on the central nervous system, is not widely recognized [10]. The enzyme 5α-reductase plays a crucial role in the metabolism of neuroactive steroids within the central nervous system. Three isoforms of this enzyme have been identified in the brain, where they participate in the conversion of testosterone and progesterone to their active metabolites of dihydrotestosterone and dihydroprogesterone, respectively.
These products are further metabolized into neuroactive derivatives such as allopregnanolone, isopregnanolone, 5α-androstan-3α,17β-diol, and 5α-androstan-3β, 17β-diol. These compounds modulate the activity of neurosteroid receptors, including the GABA-A receptor complex, thereby playing an important role in regulating emotional, cognitive, and behavioral processes [11].
As an inhibitor of type II 5α-reductase and, to a lesser extent, type I, finasteride disrupts this metabolic pathway. Such disruption may lead to significant alterations in the concentrations of neuroactive steroids in both plasma and cerebrospinal fluid.
==========
Conclusions
For lower urinary tract symptoms in patients at risk of developing PFS, phosphodiesterase type 5 inhibitors, which can improve sexual function and urinary flow without directly affecting the androgen hormonal axis, may be a treatment option. Drugs from this class, along with α-adrenergic antagonists, may serve as pharmacologic alternatives for symptomatic benign prostatic hyperplasia. If pharmacotherapy is not effective in alleviating symptoms, patients can be offered a wide range of procedural interventions tailored to their individual needs and clinical condition.
Because the pathophysiological mechanisms underlying PFS remain unknown, causal treatment is currently
not possible, and interventions are symptomatic and supportive. Current recommendations emphasize the need for an integrated biopsychosocial approach that considers biological, psychological, and social aspects. Psychological and psychiatric support plays a key role and includes cognitive behavioral therapy, treatment of coexisting depressive or anxiety disorders, with a preference for antidepressants with a minimal impact on sexual function (e.g., bupropion, mirtazapine), and sex therapy incorporating sensate focus techniques and motivational interviewing.
PDE5 inhibitors or intracavernosal injections are used to treat erectile dysfunction, and supportive measures may include supplementation with, for example, vitamin D, vitamin E, L-arginine, or L-carnitine. These supplements may positively influence nitric oxide metabolism and vascular function.
Cilio et al. [22] describe PFS as a relatively rare syndrome, with symptoms that may persist for more than a year after finasteride discontinuation. The authors also discuss several potential factors that may contribute to PFS, including androgen receptor gene polymorphisms and changes in the gut microbiota. In another study, authored by Thaibah and published in 2025 [23], an extensive dataset involving more than 9,400 participants with PFS was analyzed. The results revealed that nearly 18% of participants reported suicidal ideation and 7% had attempted suicide. Based on these findings, the European Medicines Agency formally recognized suicidal ideation as an adverse effect of finasteride at a dose of 1 mg, the dose used to treat androgenetic alopecia.
Cilio et al. [22] discussed PFS and its core side effects, which require a complex diagnostic process. The authors emphasized that the absence of clearly established pathophysiological mechanisms cannot be grounds for denying the existence of the syndrome, especially given the increasing number of consistent clinical observations.
A promising, although still experimental, area of research is the development of therapies targeting neuroactive steroids and modulation of androgen receptor expression. However, none of the available therapeutic regimens guarantees complete remission of symptoms. The goal of treatment is the gradual alleviation of symptoms and improvement of patients’ quality of life. Given the possible influence of the nocebo effect, effective communication with the patient is crucial, including ensuring that reported complaints are taken seriously and fostering a trust-based therapeutic relationship. Treatment should be implemented within an interdisciplinary framework involving physicians, psychologists, and sexologists. In every case, the decision to initiate therapy with a 5α-reductase inhibitor should be preceded by a thorough assessment of the patient’s physical and mental health and by obtaining informed consent after discussion of the potential benefits and risks